




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07C 59/68, A61K 31/19, C07C 65/24, 43/295, 255/37, A61K 31/085, 31/275, 31/66</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/00353</b>  <b>(43) International Publication Date:</b> 7 January 1999 (07.01.99)
<b>(21) International Application Number:</b> PCT/EP98/04039  <b>(22) International Filing Date:</b> 26 June 1998 (26.06.98)  <b>(30) Priority Data:</b> 9713739.2 27 June 1997 (27.06.97) GB  <b>(71) Applicant (for all designated States except US):</b> KARO BIO AB [SE/SE]; Novum, S-141 57 Huddinge (SE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LI, Yi-Lin [CN/SE]; Källbrinksvägen 38C, S-141 31 Huddinge (SE). LIU, Ye [CN/SE]; Smedvägen 23, S-146 36 Tullinge (SE). HEDFORS, Asa [SE/SE]; Domarvägen 3 nb, S-141 62 Huddinge (SE). MALM, Johan [SE/SE]; Körsångarvägen 53, S-142 40 Skogås (SE). MELLIN, Charlotta [SE/SE]; Bokvägen 8, S-146 48 Tullinge (SE). ZHANG, Minsheng [CN/US]; 31 Scheurman Terrace, Warren, NJ 07059 (US).  <b>(74) Agent:</b> WITHERS & ROGERS; 4 Dyer's Buildings, Holborn, London EC1N 2JT (GB).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

**(54) Title:** NOVEL THYROID RECEPTOR LIGANDS AND METHOD**(57) Abstract**

Novel thyroid receptor ligands as provided which have general formula (I) in which: R<sub>1</sub> is alkyl of 1 to 4 carbons or cycloalkyl of 3 to 7 carbons; R<sub>2</sub> and R<sub>3</sub> are the same or different and are hydrogen, halogen, alkyl of 1 to 3 carbons or cycloalkyl of 3 to 5 carbons, at least one of R<sub>2</sub> and R<sub>3</sub> being other than hydrogen; n is an integer from 0 to 4; R<sub>4</sub> is an aliphatic hydrocarbon, an aromatic hydrocarbon, carboxylic acid ester thereof, alkenyl carboxylic acid or ester thereof, hydroxy, halogen, cyano, or a phosphonic acid or an ester thereof, or a pharmaceutically acceptable salt thereof. A method for treating diseases associated with metabolism dysfunction or which are dependent on the expression of a T3 regulated gene (such as obesity, hypercholesterolemia, osteoporosis, hypothyroidism and goiter) is also provided.



A method for treating diseases associated with metabolism dysfunction or which are dependent on the expression of a T3 regulated gene (such as obesity, hypercholesterolemia, osteoporosis, hypothyroidism and goiter) is also provided.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL THYROID RECEPTOR LIGANDS AND METHODField of the Invention

5 This invention relates to novel compounds which are thyroid receptor ligands, and are preferably selective for the thyroid hormone receptor  $\beta$ , to methods of preparing such compounds and to methods for using such compounds such as in the regulation of metabolism.

10 Background of the Invention

While the extensive role of thyroid hormones in regulating metabolism in humans is well recognized, the discovery and development of new specific drugs for improving the treatment of hyperthyroidism and  
15 hypothyroidism has been slow. This has also limited the development of thyroid hormone agonists and antagonists for treatment of other important clinical indications, such as hypercholesterolemia, obesity and cardiac arrhythmias.

Thyroid hormones affect the metabolism of virtually  
20 every cell of the body. At normal levels, these hormones maintain body weight, the metabolic rate, body temperature, and mood, and influence serum low density lipoprotein (LDL) levels. Thus, in hypothyroidism there are weight gain, high levels of LDL cholesterol, and depression. In excess  
25 with hyperthyroidism, these hormones lead to weight loss, hypermetabolism, lowering of serum LDL levels, cardiac arrhythmias, heart failure, muscle weakness, bone loss in postmenopausal women, and anxiety.

Thyroid hormones are currently used primarily as  
30 replacement therapy for patients with hypothyroidism. Therapy with L-thyroxine returns metabolic functions to normal and can easily be monitored with routine serum measurements of levels of thyroid-stimulating hormone (TSH), thyroxine (3,5,3',5'-tetraiodo-L-thyronine, or T4)  
35 and triiodothyronine (3,5,3'-triiodo-L-thyronine, or T3). However, the rapidity with which replacement therapy can be given and in some circumstances, particularly in older

individuals, even replacement therapy, is limited by certain of the deleterious effects of thyroid hormones.

In addition, some effects of thyroid hormones may be therapeutically useful in non-thyroid disorders if adverse effects can be minimized or eliminated. These potentially useful influences include weight reduction, lowering of serum LDL levels, amelioration of depression and stimulation of bone formation. Prior attempts to utilize thyroid hormones pharmacologically to treat these disorders have been limited by manifestations of hyperthyroidism, and in particular by cardiovascular toxicity.

Development of specific and selective thyroid hormone receptor agonists could lead to specific therapies for these common disorders while avoiding the cardiovascular and other toxicities of native thyroid hormones. Tissue-selective thyroid hormone agonist may be obtained by selective tissue uptake or extrusion, topical or local delivery, targeting to cells through other ligands attached to the agonist and targeting receptor subtypes. Thyroid hormone receptor agonists that interact selectively with the  $\beta$ -form of the thyroid hormone receptor offers an especially attractive method for avoiding cardio-toxicity.

Thyroid hormone receptors (TRs) are, like other nuclear receptors, single polypeptide chains. The various receptor forms appear to be products of two different genes  $\alpha$  and  $\beta$ . Further isoform differences are due to the fact that differential RNA processing results in at least two isoforms from each gene. The TR $\alpha$ 1, TR $\beta$ 1 and TR $\beta$ 2 isoforms bind thyroid hormone and act as ligand-regulated transcription factors. In adults, the TR $\beta$ 1 isoform is the most prevalent form in most tissues, especially in the liver and muscle. The TR $\alpha$ 2 isoform is prevalent in the pituitary and other parts of the central nervous system, does not bind thyroid hormones, and acts in many contexts as a transcriptional repressor. The TR $\alpha$ 1 isoform is also widely distributed, although its levels are generally lower than those of the TR $\beta$ 1 isoform. This isoform may be

especially important for development. Whereas many mutations in the TR $\beta$  gene have been found and lead to the syndrome of generalized resistance to thyroid hormone, mutations leading to impaired TR $\alpha$  function have not been found.

5 A growing body of data suggest that many or most effects of thyroid hormones on the heart, and in particular on the heart rate and rhythm, are mediated through the  $\alpha$ -form of the TR $\alpha$ 1 isoform, whereas most actions of the hormone such as on the liver, muscle and other tissues are mediated more through the  $\beta$ -forms of the receptor. Thus, a TR $\beta$ -selective agonist might not elicit the rhythm and rate influences of the hormones but would elicit many other actions of the hormones. It is believed that the  $\alpha$ -form of the receptor is the major drive to heart rate for the following reasons:

- 1) tachycardia is very common in the syndrome of generalized resistance to thyroid hormone in which there are defective TR $\beta$ -forms, and high circulating levels of T4 and T3;
- 2) there was a tachycardia in the only described patient with a double deletion of the TR $\beta$  gene (Takeda et al, J. Clin. Endocrinol. & Metab. 1992, Vol. 74, p. 49);
- 3) a double knockout TR $\alpha$  gene (but not  $\beta$ -gene) in the mouse has a slower pulse than control mice; and,
- 4) western blot analysis of human myocardial TR's show presence of the TR $\alpha$ 1, TR $\alpha$ 2 and TR $\beta$ 2 proteins, but not TR $\beta$ 1.


If these indications are correct, then a TR $\beta$ -selective agonist could be used to mimic a number of thyroid hormone actions, while having a lesser effect on the heart. Such a compound may be used for: (1) replacement therapy in elderly subjects with hypothyroidism who are at risk for cardiovascular complications; (2) replacement therapy in elderly subjects with subclinical hypothyroidism who are at risk for cardiovascular complications; (3) obesity; (4) hypercholesterolemia due to

elevations of plasma LDL levels; (5) depression; and, (6) osteoporosis in combination with a bone resorption inhibitor.

### Description of the Invention

In accordance with the present invention, compounds are provided which are thyroid receptor ligands, and have the general formula I:

I



in which:

R<sub>1</sub> is alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons;

R<sub>2</sub> and R<sub>3</sub> are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R<sub>2</sub> and R<sub>3</sub> being other than hydrogen;

n is an integer from 0 to 4;

R<sub>4</sub> is an aliphatic hydrocarbon, an aromatic hydrocarbon, carboxylic acid or ester thereof, alkenyl carboxylic acid or ester thereof, hydroxy, halogen, cyano, or a phosphonic acid or ester thereof, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof.

In addition, in accordance with the present invention, a method for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene is provided, wherein a compound of formula I is administered in a therapeutically effective amount. The compound of formula I is preferably an agonist that is preferably selective for the thyroid hormone receptor-beta. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene

are set out hereinafter and include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma and congestive heart failure.

5

### Detailed Description of the Invention

The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances.

10

The term "thyroid receptor ligand" as used herein is intended to cover any moiety which binds to a thyroid receptor. The ligand may act as an agonist, an antagonist, a partial agonist or a partial antagonist.

15

The term "aliphatic hydrocarbon(s)" as used herein refers to acyclic straight or branched chain groups which include alkyl, alkenyl or alkynyl groups.

The term "aromatic hydrocarbon(s)" as used herein refers to groups including aryl groups as defined herein.

20

Unless otherwise indicated, the term "lower alkyl", "alkyl" or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 12 carbons (in the case of alkyl or alk), in the normal chain, preferably 1 to 4

25

carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, or isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl.

30

The term "aryl" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, hydroxy, nitro or cyano.

35

Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 12 carbons, preferably 2 to 5 carbons, in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, and the like.

Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 12 carbons, preferably 2 to 8 carbons, in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like.

Unless otherwise indicated, the term "cycloalkyl" as employed herein alone or as part of another group includes saturated cyclic hydrocarbon groups or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups, containing one ring and a total of 3 to 7 carbons, preferably 3 to 5 carbons, forming the ring, which includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl and cyclohexenyl.

The term "halogen" or "halo" as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as  $\text{CF}_3$ , with chlorine or bromine being preferred.

The term "phosphonic acid" refers to a phosphorus containing a group of the structure  $\text{—}\overset{\text{O}}{\parallel}\text{P}(\text{OR}_5)_2$  wherein  $\text{R}_5$  is H or lower alkyl.

The compounds of formula I can be present as salts, in particular pharmaceutically acceptable salts. If the compounds of formula I have, for example, at least one



basic center, they can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C<sub>1</sub>-C<sub>4</sub>)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted, for example by halogen, for example methyl- or p-toluene-sulfonic acid. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds of formula I having at least one acid group (for example COOH) can also form salts with bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl-propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine. Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds I or their pharmaceutically acceptable salts, are also included.

Preferred salts of the compounds of formula I which include a basic group include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate.


Preferred salts of the compounds of formula I which include an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amines.

5 Preferred are compounds of the invention of formula I wherein  $R_1$  is isopropyl;


$R_2$  and  $R_3$  are independently halogen such as bromo or chloro; or

$R_2$  and  $R_3$  are each methyl or one is methyl and the  
10 other is ethyl;  
or one of  $R_2$  and  $R_3$  is halogen such as bromo or chloro, and the other is alkyl such as methyl, or hydrogen;  
 $n$  is 0, 1 or 2; and

$R_4$  is carboxylic acid (COOH) or esters thereof,  
15 alkenyl carboxylic acid or esters thereof, OH, CN, halogen such as iodo, phosphonic acids or esters thereof such as



Preferred compounds of the invention have the structures



20 The compounds of formula I may be prepared by the exemplary processes described in the following reaction schemes. Exemplary reagents and procedures for these reactions appear hereinafter and in the working Examples.

25 Compounds of formula I of the invention can be prepared using the sequence of steps outlined in Schemes 1 to 5 set out below.

30 In Scheme 1, an anisole-derived iodonium salt 2 and copper bronze in an inert solvent such as dichloromethane are mixed at room temperature. A mixture of the appropriate phenol ester 1 and a base such as triethylamine in an inert solvent such as dichloromethane was added to the mixture,

generally using 2 molar equivalents each of the phenol and base, and 3 molar equivalents of iodonium salt 2. After stirring overnight at room temperature, the reacted mixture is purified via chromatography on silica gel, to give biaryl ether products 3. Other methods exist in the literature for the synthesis of diaryl ethers, for example, two references directly apply to the synthesis of thyroid hormone analogs: D. A. Evans et al., Tet. Letters, volume 39, 2937-2940 (1998) and G. M. Salamonczyk et al., Tet. Letters, volume 38, 6965-6968 (1997). The carboxylic acid ester is removed with a mixture of aqueous sodium hydroxide and methanol. Acidification of the completed reaction mixture is followed by standard work-up and crystallization or chromatography. The methyl ether function is removed by treatment of the free acid product of the previous procedure with 4-6 molar equivalents of a strong acid such as boron tribromide at 0°C in an inert solvent such as dichloromethane. The reacted mixture gives after standard work-up and purification, the end product 4 (Examples 1, 3, 4, 5 and 11). Other combinations of protecting groups for the carboxylic acid present in 1 and phenolic hydroxyl in iodonium salt 2 can be employed, and their usage is known to those skilled in the art (references describing protecting group strategy include, for example, "Protecting Groups in Organic Chemistry", J. F. W. McOmie, Plenum Press, London, New York, 1973, and "Protective Groups in Organic Synthesis", T. W. Greene, Wiley, New York, 1984).

Examples of compounds of formula I in which  $R_4 = OH$  can be prepared by further chemistry are depicted in Scheme 1. The intermediate ester product 3 can be reduced by treatment with an appropriate reducing agent such as diisobutyl aluminium hydride in an inert solvent such as THF at 0°C. If  $R_2$  and  $R_3$  are alkyl, then lithium aluminium hydride may be employed without the risk of reducing away halogen substituents at those positions. Standard work-up and purification yields the desired alcohol product 5. Other reducing agents may be employed and are known to

those skilled in the art. Removal of the phenolic protecting group as described above affords the final product alcohol 6, which are compounds of formula I in which  $R_4 = OH$  (Example 6).


5 Intermediate 5 in Scheme 1 may be converted to compounds of formula I in which  $R_4 = \text{halogen}$  by any one of a number of sequences well known to those skilled in the art. For example, 2 molar equivalents of sodium iodide can be added to a mixture of alcohol 5,  $P_2O_5$  and  $H_3PO_4$ , and  
10 heated at  $120^\circ C$  for 15 minutes, to give the intermediate iodide 7. Removal of the phenolic protecting group gives final product 8, a compound of formula I in which  $R_4 = \text{iodide}$  (Examples 2 and 7) after conventional work-up and purification. Numerous other methodologies for conversion  
15 of simple hydroxyl groups to the corresponding alkyl halide are well known to those skilled in the art.

Various extended carboxylic acid compounds of formula I ( $R_4 = COOH$ ) can be obtained from intermediate 7 in Scheme 1. For example, the anion of ethyl malonate can  
20 be stirred with alkyl iodide 7 overnight at reflux in a polar solvent such as t-butanol or dimethylformamide, employing a molar ratio of the anion, compared with the iodide, within the range of 2-3 to 1. After hydrolysis of the alkylated diester product of this reaction, the  
25 corresponding monoacid is obtained by heating the diacid to temperatures around  $180^\circ C$ . Removal of the methyl ether protecting group as described above yields the desired product 9 in which  $R_4 = COOH$  (Example 8).

Compounds of formula I in which  $R_4 = CN$  can be  
30 obtained by reacting intermediate 7 in Scheme 1 with sodium cyanide in a polar solvent or solvent mixture such as water:ethanol (1:3). The reaction may be stirred at reflux and the amount of sodium cyanide employed may be at least 5 times molar excess relative to the iodide 7 in order to  
35 drive the reaction to completion. Work-up and purification of the resulting product by standard means affords the desired nitrile product. Removal of the methyl ether group

by methods described above yields the final product 10 in which  $R_4 = \text{CN}$  (Example 9). The nitrile final products may also be converted to the corresponding carboxylic acids by standard hydrolytic procedures such as heating to around  
5 100°C in a mixture comprised of equal volumes of acetic acid, sulfuric acid and water. Standard work-up and purification affords the corresponding carboxylic acid product (Example 10).


Scheme 1



The procedures described in Scheme 2 further  
 5 exemplify methods for the synthesis of compounds of formula I. For example, the unprotected phenol, carboxylic acid intermediate 10 in Scheme 2 may be reduced by standard

means known in the art, such as reacting with 3 molar equivalents of tetrabutylammonium boronate and 4 molar equivalents of ethylbromide in a solvent mixture consisting of dichloromethane:THF:water (5:2:2). Work-up and purification by standard means affords product 11 which are compounds of the formula I in which  $R_4 = OH$  (Examples 12 and 16). The alcohol products 11 can be reacted with 0.5 molar equivalents  $PBr_3$  in an inert solvent such as dichloromethane at room temperature. The reacted mixture after work-up and purification yields the corresponding bromides 12 (Examples 13a and 17a). These alkyl bromides may be converted to compounds of formula I in which  $R_4 = CN$  by reaction with sodium cyanide in a polar solvent or solvent mixture such as water:DMF (1:9) and heating at 50°C. The reacted mixture gives after work-up and chromatography the benzylcyanide products 13 (Example 13 and 17). In addition, the bromide intermediates 13 can be converted to compounds of formula I in which  $R_4 =$  phosphonic acid diesters by reaction with trialkylphosphites under standard Arbusov reaction conditions. For example, the reaction of Example 13a with triethyl phosphite in large excess (10-12 molar equivalents versus bromide 12) in toluene at reflux for at least 2 days yields the corresponding dialkylphosphonate ester, compound 14 (Example 14) in Scheme 2. Simple hydrolysis of this product in aqueous acid solvent such as in hot hydrochloric acid gives the corresponding phosphonic acid 15 (Example 15) after work-up and purification.


## Scheme 2



5        Scheme 3 depicts a synthesis of compounds of formula  
 I in which R<sub>4</sub> = COOH and is connected to the aromatic ring  
 by an intervening double bond (alkenyl carboxylic acid). A  
 bromophenol of general structure 16 is coupled to iodonium  
 salt 17 in the same manner as described above to give the  
 10    diaryl ether product 18. Reaction of diaryl ether 18 with  
 an acrylate ester such as ethyl acrylate, using palladium  
 acetate, triphenyl phosphine and triethylamine in a solvent  
 such as acetonitrile with heating at elevated temperatures  
 gives a cinnamate ester product which, after removal of the  
 15    ester and methyl ether as described previously, gives the  
 product alkenyl carboxylic acid 19 (Example 18).




Scheme 3

Example 18, R<sub>2</sub> = R<sub>3</sub> = BrR<sub>1</sub> = isopropyl.

Examples of compounds of formula I in which R<sub>2</sub> is different from R<sub>3</sub> can be synthesized by the method shown in Scheme 4. Standard halogenation conditions are well-known to those versed in the art to convert the tri-substituted phenol ester intermediate 20 to product 21 in which R<sub>3</sub> is halogen and is different from R<sub>2</sub>. For example, iodination can be achieved by using iodine in glacial acetic acid in the dark. Similarly, bromination can be accomplished by substituting bromine under the same reaction conditions. The product phenol 21 is then coupled to iodonium salt 2 to give the diaryl ether product 22. The ester group R and the methyl ether protecting groups are removed by procedures already described above to give the final product 23 where R<sub>3</sub> is halogen and is different from R<sub>2</sub> (Examples 19, 20 and 26).


Scheme 4



- 5 Compounds of formula I in which  $R_2 = \text{Cl}$  and  $R_3 =$   
 alkyl can be prepared by the methods shown in Scheme 5.  
 The intermediate 24 in which  $R_2 = \text{Cl}$  and  $R_3$  may be either Br  
 of I can be alkylated under standard Stille conditions such  
 as using tetramethyl tin  $[(\text{Me})_4\text{Sn}]$  or tetraethyl tin  
 10  $[(\text{Et})_4\text{Sn}]$  in the presence of  
 tetrakis(triphenylphosphine)palladium in a solvent such as  
 toluene. Heating this mixture in the dark under an inert  
 atmosphere yields, after normal work-up and purification,  
 the product 25 in which  $R_2 = \text{Cl}$  and  $R_3 = \text{alkyl}$ . Removal of  
 15 the methyl ether and ester protecting groups under standard  
 conditions well-known to those versed in the art yields the  
 final product 26 (Examples 21 and 22).

The reduction product 27 (Example 23) was obtained  
 under the reaction conditions described in Scheme 5.

Scheme 5



5 With respect to the above reaction schemes, although the various  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $n$  moieties are specifically defined, unless otherwise indicated, it is to be understood that  $R_1$ ,  $R_2$ ,  $R_3$ , and  $R_4$  may be any of the groups encompassed thereby and  $n$  may be 0, 1, 2, 3 or 4.

10 The compounds of the invention are agonists, that are preferably selective for the thyroid hormone receptor-beta, and as such are useful in the treatment of obesity, hypercholesterolemia and atherosclerosis by lowering of serum LDL levels, alone or in combination with a

15 cholesterol lowering drug such as an HMG CoA reductase inhibitor, amelioration of depression alone or in combination with an antidepressant, and stimulation of bone formation to treat osteoporosis in combination with any known bone resorption inhibitor such as alendronate sodium.

20 In addition, the compounds of the invention may be useful as replacement therapy in elderly patients with hypothyroidism or subclinical hypothyroidism who are at

risk for cardiovascular complications, and in the treatment of non-toxic goiter; in the management of papillary or follicular thyroid cancer (alone or with T<sub>4</sub>); in the treatment of skin disorders such as psoriasis, glaucoma, cardiovascular disease such as in the prevention or treatment of atherosclerosis, and congestive heart failure.

The compounds of the invention can be administered orally or parenterally such as subcutaneously or intravenously, as well as by nasal application, rectally or sublingually to various mammalian species known to be subject to such maladies, e.g., humans, cats, dogs and the like in an effective amount within the dosage range of about 0.1 to about 100 mg/kg, preferably about 0.2 to about 50 mg/kg and more preferably about 0.5 to about 25 mg/kg (or from about 1 to about 2500 mg, preferably from about 5 to about 2000 mg) on a regimen in single or 2 to 4 divided daily doses.

The active substance can be utilized in a composition such as tablet, capsule, solution or suspension or in other type carrier materials such as transdermal devices, iontophoretic devices, rectal suppositories, inhalant devices and the like. The composition or carrier will contain about 5 to about 500 mg per unit of dosage of a compound of formula I. They may be compounded in conventional matter with a physiologically acceptable vehicle or carrier, excipient, binder, preservative, stabilizer, flavor, etc., as called for by accepted pharmaceutical practice.

The following working Examples represent preferred embodiments of the present invention.

#### Example 1

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoic acid

(a) To a suspension of bis(3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (prepared by the method of Yokayama et al, Journal of Medicinal Chemistry

1995, 38, 695-707) (37 g) and copper bronze (6.1 g) in dichloromethane (150 ml), was added a solution of methyl 3,5-dibromo-4-hydroxybenzoate (15 g) and triethylamine (5.4 g) in dichloromethane (100 ml) dropwise at room  
5 temperature. The mixture was stirred overnight and then filtrated through Celite. After concentration, the resulting residue was passed through a short silica gel column eluted with ethyl acetate/light petroleum ether (5/95). The pure fractions were pooled and concentrated to  
10 dryness. The residue was recrystallized from methanol affording 19.5 g (89%) of methyl 3,5-dibromo -4-(4'-methoxy-3'-isopropylphenoxy)-benzoate.

(b) The above ester (6.5 g) was hydrolysed by treatment with 1 M aqueous NaOH (60 ml) and methanol (150  
15 ml) to give 3,5-dibromo -4-(4'-methoxy-3'-isopropylphenoxy)benzoic acid (6.3 g, 99%).

(c) The above ester (2 g) was demethylated with boron tribromide (1M, 26 ml) in methylene chloride at 0°C. The mixture was stirred overnight at room temperature  
20 before quenching with a water/ice mixture. The layers were separated and the water layer extracted with methylene chloride. The combined organic extracts were dried, filtered and concentrated. The resulting residue was recrystallized to give 3,5-dibromo-4-(4-hydroxy-3-  
25 isopropylphenoxy)benzoic acid (1.85 g, 98%).

### Example 2

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzyl iodide

30 a) Methyl 3,5-dibromo-4-(4-methoxy-3-isopropylphenoxy)-benzoate (Example 1a) (4.6 g) was treated with a 1 M solution of diisobutyl aluminium hydride (DIBAL) in THF (40 ml) at 0°C and then warmed to room temperature and stirred for 1 hour. The reaction mixture was poured into  
35 an ice-cold 1 M HCl solution and extracted with ethyl acetate 3 times. The organic layer was washed (brine), dried, filtered and concentrated to dryness affording 3,5-

dibromo-4-(4-methoxy-3-isopropylphenoxy)benzylalcohol (4.15 g, 96%) as oil which became a white solid after standing.

b) The above alcohol (215 mg) was added into a mixture of  $P_2O_5$  (36 mg) and  $H_3PO_4$  (490 mg) followed by  
5 addition of sodium iodide (150 mg). The mixture was stirred at 120°C for 15 min and then partitioned between water and ethyl acetate. The organic layer was washed with  $Na_2S_2O_3$  and brine, dried, filtered and concentrated. The  
10 residue was crystallized from petroleum ether to give 3,5-dibromo-4-(4-methoxy-3-isopropylphenoxy)-benzyl iodide (170 mg, 63%).

c) The above iodide (300 mg) was demethylated with boron tribromide to give 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzyl iodide (220 mg, 75%).

15

### Example 3

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid.

20 a) Bromine (35.2 g) was added dropwise to a suspension of methyl 4-hydroxy-phenylacetate (16.6 g) in  $H_2O$  (500 ml). After 1 day stirring, the mixture was partitioned between  $H_2O$  and ethyl acetate. The organic  
25 layer was washed with aqueous sodium thiosulfate, dried, filtered and concentrated. The residue was recrystallized from methanol to give 16 g of methyl 3,5-dibromo-4-hydroxy-phenylacetate as a light yellow solid (49%).

b) The above phenol (5 g) was coupled to bis(3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (9.5  
30 g) as described in Example 1a. Purification by column chromatography and recrystallization from methanol gave 7.3 g (83%) of methyl 3,5-dibromo-4-(4-methoxy-3-isopropylphenoxy)phenylacetate.

c) The above ester (2.4 g) was demethylated with  
35 boron tribromide as described in Example 2c. The crude product was recrystallized from dichloromethane and light

petroleum ether to give 1.37 g of 3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)phenylacetic acid (62%).

#### Example 4

5 3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylpropionic acid

(a) Methyl 4-hydroxy-phenylpropionate (9b) was brominated using the method described in Example 3a to give  
10 15.8 g (93.5%) of methyl 3,5-dibromo-4-hydroxy-phenylpropionate a light yellow solid.

(b) The above phenol (3.4g) was coupled to bis(3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (7.7 g) using the method described in Example 1a to give 2.8 g  
15 (60%) of methyl 3,5-dibromo-4-(4-methoxy-3-isopropylphenoxy)phenylpropionate.

(c) The above ester (2.4 g) was demethylated with boron tribromide using the method described in Example 1c. The crude product was recrystallized from dichloromethane and light petroleum ether to give 1.37 g (62%) of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylpropionic acid.  
20

#### Example 5

25 3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoic acid.

(a) Methyl 3,5-dichloro-4-hydroxybenzoate (10 g) was coupled with bis(3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (35 g) using the method described in  
30 Example 1a. Purification by column chromatography (silica gel, 95:5 light petroleum ether/ethylacetate) followed by recrystallization from methanol gave 8.42 g (51%) of methyl 3,5-dichloro-4-(4-methoxy-3-isopropylphenoxy)benzoate.

35 (b) The above methoxy compound (100 mg) was demethylated and hydrolysed using the method described in

Example 1c to give 65 mg (71%) of 3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoic acid.

#### Example 6

5 3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzylalcohol.

a) Methyl 3,5-dichloro-4-(4-methoxy-3-isopropylphenoxy)benzoate (Example 5a) (3.0 g) was treated with a 1 M solution of diisobutyl aluminium hydride (DIBAL) in THF  
10 (32.5 ml) at 0°C and then warmed to room temperature and stirred overnight. The reaction mixture was poured into an ice-cold 1 M HCl solution and extracted with ethyl acetate three times. The organic layer was washed (brine), dried, filtered and concentrated to dryness affording 3,5-  
15 dichloro-4-(4-methoxy-3-isopropylphenoxy)benzylalcohol (3.21 g, 100%) as an oil.

b) The above alcohol (200 mg) was demethylated using the method described in Example 1c to give 104 mg  
20 (59%) of 3,5 dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzylalcohol.

#### Example 7

3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzyl iodide.

25 a) 3,5-Dichloro-4-(4-methoxy-3-isopropylphenoxy)benzylalcohol (3.21 g) (Example 6a) was added into a mixture of P<sub>2</sub>O<sub>5</sub> (576 mg) and H<sub>3</sub>PO<sub>4</sub> (5.5 ml) followed by addition of sodium iodide (2.43 g). The mixture was stirred at 120°C for 15 min and then partitioned between  
30 water and ethyl acetate. The organic layer was washed with an aqueous solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> and brine, dried, filtered and concentrated. The residue was crystallized from petroleum ether to give 2.9 g (79%) of 3,5-dichloro-4-(4-methoxy-3-isopropylphenoxy)benzyl iodide.

35 b) The above iodide (130 mg) was demethylation using the method described in Example 1c to give 76 mg



(60%) of 3,5 dichloro-4-(4-hydroxy-3-isopropylphenoxy)-benzyliodide.

#### Example 8

5 3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylpropionic acid.

a) Sodium (46 mg) in small pieces was added into a dry flask containing t-butanol. The mixture was refluxed  
10 for 1 hour or until the sodium was completely dissolved. Ethyl malonate (320 mg) was added and the reaction mixture was warmed at 90°C for 1 hour followed by addition of the iodide (Example 7a, 451 mg) in portions. The mixture was stirred under reflux for three hours and concentrated. The  
15 residue was stirred under reflux with potassium hydroxide and water (1:1) overnight. The resulting residue was partitioned between ethyl acetate and concentrated Hcl. The organic layer was dried, filtered and concentrated to give a white solid which was transferred into a small flask  
20 which was heated at 180°C for three hours. The resulting residue was chromatographed on silica gel and eluted with methanol/chloroform (1/9). The pure fractions were pooled and concentrated affording 3,5-Dichloro-4-(4-methoxy-3-isopropylphenoxy)phenylpropionic acid (152 mg, 20%).

25 b) The above acid (116 mg) was demethylated with boron trifluoride dimethylsulfide complex to give 3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylpropionic acid (33 mg, 30%).

#### Example 9

30 3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetonitrile.

a) To a solution of sodium cyanide (400 mg) in  
35 water (1 ml), the above iodide (Example 7a, 900 mg) in absolute ethanol (3 ml) was added. The reaction mixture became homogeneous after heating and was stirred under

reflux for 2 hours. The reaction mixture was poured into crushed ice and partitioned between water and ethyl acetate. The organic layer was dried, filtered and concentrated and the residue was chromatographed on silica gel and eluted with ethyl acetate/petroleum ether (1/8). The pure fractions were pooled and concentrated to give 3,5-dichloro-4-(4-methoxy-3-isopropylphenoxy)phenylacetonitrile (440 mg, 63%).

b) The above methoxynitrile (170 mg) was demethylated using the method described in Example 1c to give 3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetonitrile (147 mg, 90%).

#### Example 10

3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid.

To a solution of nitrile 9b (760 mg) dissolved in acetic acid (10 ml) was added dropwise a mixture of concentrated sulfuric acid (10 ml) and water (10 ml) was added dropwise. The reaction mixture was heated at 105°C for 3 hours and partitioned between ice-cold water and ethyl acetate. The organic layer was dried, filtered and concentrated to give 3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid (638 mg, 77%).

#### Example 11

3,5-Dimethyl-4-(4-hydroxy-3-isopropylphenoxy)benzoic acid.

(a) Methyl 3,5-dimethyl-4-hydroxybenzoate (5.2 g) was coupled with bis(3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (22.1 g) using the method described in Example 1(a). Purification by column chromatography (silica gel, 97:3 light petroleum ether/ethylacetate) gave 8.3 g (87%) of methyl 3,5-dichloro-4-(4-methoxy-3-isopropylphenoxy)benzoate.

(b) The above methoxy compound (5 g) was demethylated and hydrolysed using the method described in Example 1(c). The residue was subjected to column chromatography (silica gel, 98:2:0.3 chloroform/  
5 methanol/acetic acid) to give 1.22 g (27%) of the title compound.

#### Example 12

10 3,5-Dibromo -4-(4-hydroxy-3-isopropylphenoxy)benzylalcohol.

A mixture of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoic acid (Example 1(c)) (1.0 g, 3.3 mmol), tetrabutylammonium boronate (2.6 g, 9.9 mmol) and ethylbromide (1.0 ml, 13.2 mmol) in 25 ml of CH<sub>2</sub>Cl<sub>2</sub> and 10  
15 ml of tetrahydrofuran was stirred at room temperature over night. The reaction mixture was treated with 1M HCl and extracted several times with EtOAc. The combined organic phases were washed once with water followed by a saturated solution of NaCl. After drying over MgSO<sub>4</sub>, filtration and  
20 evaporation, the residue was purified by column chromatography (silica gel, 7:3 p-ether/EtOAc). This gave 0.922 g (98%) of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzylalcohol.

25

#### Example 13

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzylcyanide.

(a) A solution of PBr<sub>3</sub> (125 mg, 0.463mmol) in 5 ml of CH<sub>2</sub>Cl<sub>2</sub> was added dropwise, under nitrogen, to a stirred  
30 solution of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzylalcohol (Example 12) (385mg, 0.925 mmol) in 20ml CH<sub>2</sub>Cl<sub>2</sub> at 0°C. The reaction mixture was left to stand at room temperature over night and then diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was washed with water, dried over MgSO<sub>4</sub>  
35 and concentrated. The residue was purified by column chromatography (silica gel, 75:25 petroleum-ether/EtOAc)

to give 160mg ( 36%) of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzylbromide.

(b) To a stirred solution the above bromide (135mg, 0.282 mmol) in 0.85 ml of DMF and 0.09 ml of water at 50°C, NaCN (17 mg, 0.352 mmol) was added. After 30 minutes the reaction mixture was concentrated, treated with water and extracted twice with EtOAc. The combined organic phases were dried over MgSO<sub>4</sub>, filtered and concentrated. The residue was purified by column chromatography (silica gel, 8:2 petroleum-ether/EtOAc) to give 80mg (67%) of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzylcyanide.

#### Example 14

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzyl-phosphonic acid, diethyl ester.

A mixture of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzylbromide (Example 13a) (491 mg, 1.03 mmol), triethyl phosphite (3.98 g, 12 mmol) in 20 ml of toluene was refluxed for 48 hours. The reaction mixture was concentrated and the residue was precipitated with a mixture of petroleum ether and EtOAc (8:2) to give 308 mg (0.577 mmol, 56%) of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzyl phosphonic acid, diethyl ester as a white solid.

#### Example 15

3,5-Dibromo -4-(4-hydroxy-3-isopropylphenoxy)benzyl-phosphonic acid.

A mixture of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy) benzyl phosphonic acid, diethyl ester (21 mg, 0.0392 mmol) in 2 ml of 6 M HCl was refluxed for 24 hours. The reaction mixture was concentrated and the residue was recrystallized with EtOH/water to give 10 mg (0.021 mmol, 53%) of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzylphosphonic acid as white crystals.

Example 16

3,5-Dimethyl-4-(4-hydroxy-3-isopropylphenoxy)benzylalcohol.

5           A mixture consisting of the above acid (Example 11b, 1.0 g), tetrabutylammonium boronate (2.6 g, 9.9 mmol) and ethylbromide (1.0 ml, 13.2 mmol) in 25 ml of CH<sub>2</sub>Cl<sub>2</sub> and 10 ml of tetrahydrofuran was stirred at room temperature over night. The reaction mixture was treated with 1M HCl and  
10       extracted several times with EtOAc. The combined organic phases were washed once with water followed by a saturated solution of NaCl. After drying over MgSO<sub>4</sub>, filtration and evaporation, the residue was purified by column  
chromathography (silica gel, 7:3 p-ether/EtOAc). This gave  
15       0.922 g (98%) of the title compound.

Example 17

3,5-Dimethyl-4-(4-hydroxy-3-isopropylphenoxy)phenyl-acetonitrile.

20

(a) A solution of PBr<sub>3</sub> (401 mg, 1.48 mmol) in 10 ml of CH<sub>2</sub>Cl<sub>2</sub> was added dropwise, under nitrogen, to a stirred solution of the above alcohol (Example 16, 850 mg) in 20ml CH<sub>2</sub>Cl<sub>2</sub> at 0°C. The reaction mixture was left to stand at  
25       room temperature over night and then diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was washed with water, dried over MgSO<sub>4</sub> and concentrated. The residue was purified by column  
chromathography (silica gel, 9:1 petroleum-ether/EtOAc) to  
give 465 mg of 3,5-dimethyl-4-(4-hydroxy-3-isopropyl-  
30       phenoxy)benzylbromide

b) To a stirred refluxed solution of the above nitrile (325 mg) in 2.0 ml of DMF and 0.2 ml of water, NaCN (42 mg) was added. After 2 hours the reaction mixture was concentrated, treated with water and extracted twice with  
35       EtOAc. The combined organic phases were dried over MgSO<sub>4</sub>, filtered and concentrated. The residue was purified by

column chromatography (silica gel, 8:2 petroleum-ether/EtOAc) to give 171 mg (85%) of the title compound.

#### Example 18

5 3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)cinnamic acid.

(a) 2,4,6-Tribromo-phenol (3.15g) was coupled to bis(3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (7.7 g) using the method described in Example 1(a).

10 Purification by column chromatography and recrystallization from methanol gave 4.5 g (94%) of methyl 1,3,5-tribromo-4-(4-methoxy-3-isopropylphenoxy)benzene.

b) A mixture of above tribromobenzene, (2.9g) ethyl acrylate(0.9), palladium acetate (23mg), triethylamine  
15 (0.6g), triphenylphosphine (30mg) in acetonitrile was stirred at 120°C for 5 days. Purification by column chromatography and recrystallization from methanol gave 300mg (12%) of ethyl 3,5-dibromo -4-(4-methoxy-3-isopropylphenoxy)cinnamate.

20 c) The above ester (2.4 g) was demethylated with boron tribromide using the method described in Example 2(c). The crude product was recrystallized from dichloromethane and light petroleum ether to give 1.37 g of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)cinnamic acid  
25 (62%). KB 131 109.

#### Example 19

3-Bromo-5-chloro-4-(4-hydroxy-3-isopropylphenoxy)-phenylacetic acid

30

a) To a solution of 3-chloro-4-hydroxyphenylacetic acid (2.5 g) in glacial acetic acid (35 mL) was added 0.8 mL of neat bromine carefully while stirring. The mixture was stirred in dark at ambient temperature for 51 h. The  
35 resulting mixture was diluted with water, extracted with ethyl acetate, dried and concentrated in vacuo to afford 3-bromo-5-chloro-4-hydroxyphenylacetic acid. This crude

product was dissolved in methanol (15 mL), treated with concentrated sulfuric acid (1 mL) carefully, stirred at reflux for 18 h. Cooled reaction mixture was concentrated under reduced pressure, diluted with water carefully, extracted with dichloromethane. The combined organic layers were dried and concentrated. Flash column chromatography on silica gel with ethyl acetate/hexane (0-50% gradient elution) afforded 3-bromo-5-chloro-4-hydroxyphenylacetic acid methyl ester (2.5 g, 68%).

10           b) 3-Bromo-5-chloro-4-hydroxyphenylacetic acid methyl ester (1.1 g) was coupled with bis (3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (2.9 g) by the procedure described in Example 1(a) to afford 3-bromo-5-chloro-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid methyl ester (1.1 g, 67%).

15           c) A solution of the above product (32 mg) in dichloromethane (2 mL) was treated with boron tribromide (1 M, 1 mL) under nitrogen and stirred at ambient temperature for two days. The reaction mixture was poured to stirring water and extracted with ethyl acetate from 1 N HCl. The combined organic layers were dried and concentrated. The desired 3-bromo-5-chloro-4-(4-hydroxy-3-isopropylphenoxy)-phenylacetic acid was purified using reverse-phase preparative HPLC eluting with methanol/water (30-90%) (15 mg, 50%).

#### Example 20

3-chloro-5-iodo-4-(4-hydroxy-3-isopropylphenoxy)-phenylacetic acid

30

          a) To a solution of 3-chloro-4-hydroxyphenylacetic acid (1.25 g) in glacial acetic acid (20 mL) was added 2.0 g of iodine crystals while stirring. The mixture was stirred in dark at ambient temperature for 2 days. The resulting mixture was diluted with water, extracted with ethyl acetate, dried and concentrated in vacuo to afford 3-chloro-5-iodo-4-hydroxyphenylacetic acid. This crude

product was dissolved in methanol (30 mL), treated with concentrated sulfuric acid (2 mL) carefully, stirred at reflux for 20 h. Cooled reaction mixture was concentrated under reduced pressure, diluted with water, extracted with dichloromethane. The combined organic layers were dried and concentrated. Flash column chromatography on silica gel with ethyl acetate/hexane (0-50% gradient elution) afforded 3-chloro-5-iodo-4-hydroxyphenylacetic acid methyl ester (90 mg, 4%).

10           b) 3-Chloro-5-iodo-4-hydroxyphenylacetic acid methyl ester (90 mg) was coupled with bis (3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (310 mg) by the procedure described in Example 1(a) to afford 3-chloro-5-iodo-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid methyl ester (70 mg, 54%).

15           c) A solution of the above product (30 mg) in dichloromethane (2 mL) was treated with boron tribromide (1 M, 1 mL) under nitrogen and stirred at ambient temperature for 22 h. The reaction mixture was poured to stirring water and extracted with ethyl acetate from 1 N HCl. The combined organic layers were dried and concentrated. The desired 3-chloro-5-iodo-4-(4-hydroxy-3-isopropylphenoxy)-phenylacetic acid was purified using reverse-phase preparative HPLC eluting with methanol/water (30-90%) (18 mg, 64%).

#### Example 21

3-Chloro-5-methyl-4-(4-hydroxy-3-isopropylphenoxy)-phenylacetic acid

30

          a) A solution of 3-bromo-5-chloro-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid methyl ester (50 mg) in toluene (2 mL) in a pressure tube was degassed with nitrogen, treated with tetrakis(triphenylphosphine)-palladium (47 mg) and tetramethyltin (0.3 mL) sequentially at ambient temperature. The pressure tube was then sealed and wrapped with aluminum foil. The reaction mixture was



stirred at 140 °C in dark for 22 h. Cooled reaction mixture was chromatographed on silica gel with ethyl acetate/hexane (0-25% gradient elution) afforded 3-chloro-5-methyl-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid methyl ester (36 mg, 85%).

b) A solution of the above product (36 mg) in dichloromethane (2 mL) was treated with boron tribromide (1 M, 1 mL) under nitrogen and stirred at ambient temperature for 29 h. The reaction mixture was poured to stirring water and extracted with ethyl acetate from 1 N HCl. The combined organic layers were dried and concentrated. The desired 3-chloro-5-methyl-4-(4-hydroxy-3-isopropylphenoxy)-phenylacetic acid was purified using reverse-phase preparative HPLC eluting with methanol/water (30-90%) (16 mg, 48%).

#### Example 22

3-Chloro-5-ethyl-4-(4-hydroxy-3-isopropylphenoxy)-phenylacetic acid

a) A solution of 3-bromo-5-chloro-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid methyl ester (50 mg) in toluene (2 mL) in a pressure tube was degassed with nitrogen, treated with tetrakis(triphenylphosphine)-palladium (25 mg) and tetraethyltin (0.3 mL) sequentially at ambient temperature. The pressure tube was then sealed and wrapped with aluminum foil. The reaction mixture was stirred at 140°C in dark for 17 h. Cooled reaction mixture was chromatographed on silica gel with ethyl acetate/hexane (0-25% gradient elution) afforded 3-chloro-5-ethyl-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid methyl ester (40 mg, 90%).

b) A solution of the above product (40 mg) in dichloromethane (2 mL) was treated with boron tribromide (1 M, 1 mL) under nitrogen and stirred at ambient temperature for 20 h. The reaction mixture was poured to stirring water and extracted with ethyl acetate from 1 N HCl. The

combined organic layers were dried and concentrated. The desired 3-chloro-5-ethyl-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid was purified using reverse-phase preparative HPLC eluting with methanol/water (30-90%) (5 mg, 13%).

#### Example 23

3-Chloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid

10           A solution of 3-bromo-5-chloro-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid methyl ester (100 mg) in toluene (2 mL) in a pressure tube was degassed with nitrogen, treated with tetrakis(triphenylphosphine)-palladium (54 mg) and tetraisopropyltin (0.5 mL)

15 sequentially at ambient temperature. The pressure tube was then sealed and wrapped with aluminum foil. The reaction mixture was stirred at 140°C in dark for 22 h. Cooled reaction mixture was chromatographed on silica gel with ethyl acetate/hexane (0-25% gradient elution) afforded 3-

20 chloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid methyl ester. A solution of this product in dichloromethane (2 mL) was treated with boron tribromide (1 M, 1 mL) under nitrogen and stirred at ambient temperature for 3 h. The reaction mixture was poured to stirring water and extracted with ethyl acetate from 1 N HCl. The

25 combined organic layers were dried and concentrated. The residue was dissolved in THF:MeOH:H<sub>2</sub>O (3:1:1, 2 mL), treated with LiOH (20 mg) in one portion and stirred at ambient temperature for 19 h. The reaction mixture was

30 extracted with ethyl acetate from 1 N HCl, dried, and concentrated. 3-chloro-4-(4-hydroxy-3-isopropylphenoxy)-phenylacetic acid was purified using reverse-phase preparative HPLC eluting with methanol/water (30-90%) (12 mg, 16%).

### Example 24

3,5-dimethyl-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic  
acid

5 A solution of 3,5-dibromo-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid (25 mg) in dimethylformaldehyde (1 mL) in a pressure tube was degassed with nitrogen, treated with tetrakis(triphenylphosphine)-palladium (12 mg) and tetramethyltin (0.3 mL) sequentially  
10 at ambient temperature. The pressure tube was then sealed and wrapped with aluminum foil. The reaction mixture was stirred at 140°C in dark for 23 h. Cooled reaction mixture was filtered through celite, rinsed with ethyl acetate. The filtrate was extracted with ethyl acetate from 1 N HCl,  
15 dried, and concentrated. Reverse-phase preparative HPLC eluting with methanol/water (30-90%) afforded 3,5-dimethyl-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid (9 mg, 50%).

20 Example 25

3-Ethyl-5-methyl-4-(4-hydroxy-3-isopropylphenoxy)-  
phenylacetic acid

A solution of 3,5-dibromo-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid methyl ester (37 mg) in toluene (2 mL) in a pressure tube was degassed with nitrogen, treated with tetrakis(triphenylphosphine)palladium (17 mg), tetraethyltin (0.1 mL) and tetramethyltin (0.1 mL) sequentially at ambient temperature. The pressure tube was then sealed and wrapped with aluminum foil. The reaction mixture was stirred at 140°C in dark for 22 h. Cooled reaction mixture was chromatographed on silica gel with ethyl acetate/hexane (0-25% gradient elution) afforded a mixture of products. A solution of these products in dichloromethane (2 mL) was treated with boron tribromide (1 M, 1 mL) under nitrogen and stirred at ambient temperature for 24 h. The reaction mixture was poured to stirring

water and extracted with ethyl acetate from 1 N HCl. The combined organic layers were dried and concentrated. The desired 3-ethyl-5-methyl-4-(4-hydroxy-3-isopropylphenoxy) phenylacetic acid was purified using reverse-phase  
5 preparative HPLC eluting with methanol/water (30-90%) (4 mg, 15%).

#### Example 26

3-Bromo-5-methyl-4-(4-hydroxy-3-isopropylphenoxy)-  
10 phenylacetic acid

a) To a solution of 4-methoxy-3-methylphenylacetic acid (0.43 g) in glacial acetic acid (7 mL) was added 0.2 mL of neat bromine carefully while stirring. The mixture  
15 was stirred in dark at ambient temperature for 27 h. The resulting mixture was diluted with brine, extracted with ethyl acetate, dried and concentrated in vacuo to afford 3-bromo-5-methyl-4-methoxyphenylacetic acid. This crude product was dissolved in methanol (30 mL), treated with  
20 concentrated sulfuric acid (1 mL) carefully, stirred at reflux for 16 h. Cooled reaction mixture was concentrated under reduced pressure, diluted with brine, extracted with ethyl acetate. The combined organic layers were dried and concentrated in vacuo. The residue was dissolved in  
25 dichloromethane (10 mL), treated with boron tribromide (1 M, 2 mL) under nitrogen and stirred at ambient temperature for 1 h. The reaction mixture was poured to stirring water and extracted with ethyl acetate from 1 N HCl. The combined organic layers were dried and concentrated. Flash  
30 column chromatography on silica gel with ethyl acetate/hexane (0-50% gradient elution) afforded 3-bromo-5-methyl-4-hydroxyphenylacetic acid methyl ester (0.21 g, 34%).


b) 3-Bromo-5-methyl-4-hydroxyphenylacetic acid  
35 methyl ester (0.2 g) was coupled with bis (3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (0.7 g) by the procedure described in Example 1(a) to afford 3-bromo-5-

methyl-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid methyl ester (0.15 g, 48%).

c) A solution of the above product (84 mg) in dichloromethane (3 mL) was treated with boron tribromide (1 M, 2 mL) under nitrogen and stirred at ambient temperature for 4 h. The reaction mixture was poured to stirring water and extracted with ethyl acetate from 1 N HCl. The combined organic layers were dried and concentrated. The desired 3-bromo-5-methyl-4-(4-hydroxy-3-isopropylphenoxy)-phenylacetic acid was purified using reverse-phase preparative HPLC eluting with methanol/water (30-90%) (25 mg, 32%).

What is claimed is:

1. A compound having the formula



- 5 wherein

R<sub>1</sub> is alkyl of 1 to 4 carbons or cycloalkyl of 3 to 7 carbons;

- 10 R<sub>2</sub> and R<sub>3</sub> are the same or different and are hydrogen, halogen, alkyl of 1 to 3 carbons or cycloalkyl of 3 to 5 carbons, at least one of R<sub>2</sub> and R<sub>3</sub> being other than hydrogen;

n is an integer from 0 to 4;

- 15 R<sub>4</sub> is an aliphatic hydrocarbon, an aromatic hydrocarbon, carboxylic acid or ester thereof, alkenyl carboxylic acid or esters thereof, hydroxy, halogen, cyano, or a phosphonic acid or ester thereof, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof.

- 20 2. The compound as defined in Claim 1 wherein n is 0 or 1 or 2.

3. The compound as defined in Claim 1 wherein R<sub>2</sub> and R<sub>3</sub> are each independently halogen.

4. The compound as defined in Claim 1 wherein R<sub>2</sub> and R<sub>3</sub> are each independently an alkyl group.

- 25 5. The compound as defined in Claim 1 wherein one of R<sub>2</sub> and R<sub>3</sub> is halogen and the other is an alkyl group.

6. The compound as defined in Claim 1 wherein one of R<sub>2</sub> and R<sub>3</sub> is halogen and the other is hydrogen.

- 30 7. The compound as defined in Claim 1 wherein one of R<sub>2</sub> and R<sub>3</sub> is alkyl and the other is hydrogen.

8. The compound as defined in Claim 1 wherein R<sub>2</sub> and R<sub>3</sub> are independently Cl, Br, methyl or ethyl.

9. The compound as defined in Claim 1 wherein R<sub>1</sub> is isopropyl.

10. The compound as defined in Claim 1 wherein R<sub>4</sub> is carboxyl, halogen, hydroxy, cyano, an alkenoic acid residue, or a phosphonic acid.

11. The compound as defined in Claim 1 which is
- 5 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoic acid,  
3,5-dibromo -4-(4-hydroxy-3-isopropylphenoxy)-  
benzyl iodide,  
3,5-dibromo -4-(4-hydroxy-3-isopropylphenoxy)-  
phenylacetic acid,  
10 3,5-dibromo -4-(4-hydroxy-3-isopropylphenoxy)-  
phenylpropionic acid,  
3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoic  
acid,  
3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)-  
15 benzyl alcohol,  
3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)-  
benzyl iodide,  
3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)-  
phenylpropionic acid,  
20 3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)-  
phenylacetonitrile,  
3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)-  
phenylacetic acid,  
3,5-dimethyl-4-(4-hydroxy-3-isopropylphenoxy)benzoic  
25 acid,  
3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-  
benzyl alcohol,  
3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-  
benzyl cyanide,  
30 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzyl  
phosphonic acid, diethyl ester,  
3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-  
benzylphosphonic acid,  
3,5-dimethyl-4-(4-hydroxy-3-isopropylphenoxy)-  
35 benzyl alcohol,  
3,5-dimethyl-4-(4-hydroxy-3-isopropylphenoxy)-  
phenylacetonitrile,

3,5-dibromo -4-(4-hydroxy-3-isopropylphenoxy) -  
cinnamic acid,

3-bromo-5-chloro-4-(4-hydroxy-3-isopropylphenoxy) -  
phenylacetic acid,

5 3-chloro-5-iodo-4-(4-hydroxy-3-isopropylphenoxy) -  
phenylacetic acid,

3-chloro-5-methyl-4-(4-hydroxy-3-isopropylphenoxy) -  
phenylacetic acid,

3-chloro-5-ethyl-4-(4-hydroxy-3-isopropylphenoxy) -  
10 phenylacetic acid,

3-chloro-4-(4-hydroxy-3-isopropylphenoxy) -  
phenylacetic acid,


3,5-dimethyl-4-(4-hydroxy-3-isopropylphenoxy) -  
phenylacetic acid,

15 3-ethyl-5-methyl-4-(4-hydroxy-3-isopropylphenoxy) -  
phenylacetic acid,

3-bromo-5-methyl-4-(4-hydroxy-3-isopropylphenoxy) -  
phenylacetic acid,

or a pharmaceutically acceptable salt thereof.

20 12. The compound as defined in Claim 1 having the  
structure




25 13. A method for preventing, inhibiting or treating  
a disease associated with metabolism dysfunction, or which  
is dependent on the expression of a T3 regulated gene,  
which comprises administering to a patient in need of  
treatment a therapeutically effective amount of a compound  
30 as defined in Claim 1.



14. The method as defined in Claim 13 wherein the disease associated with metabolism dysfunction or which is dependent on the expression of a T3 regulated gene is obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer, glaucoma, cardiac arrhythmia, or congestive heart failure.

15. A thyroid receptor ligands according to the following formula




10

in which  $R_2$  and  $R_3$  are the same or different and are hydrogen, halogen or alkyl of 1 to 3 carbons,  $n$  is an integer between 0 and 4 and  $R_4$  is selected from aliphatic and aromatic hydrocarbons, carboxylic acid or ester thereof, alkenyl carboxylic acid or ester thereof, hydroxy, halogen, cyano and phosphonic acid or ester thereof, such as  $\text{P}(\text{OR}')_2$  where  $R'$  is H or lower alkyl.


16. The thyroid receptor ligand according to Claim 15, in which  $R_2$  and  $R_3$  are the same or different and are chlorine, bromine or methyl.

17. A method of producing a thyroid receptor ligand according to Claim 15 which comprises reacting a compound of Formula II below with a compound of Formula III below, and demethylating the reaction product, to produce the ligand

II



## III



where Hal is halogen.

18. The use of a compound according to Claim 1 in  
5 the preparation of a medicament for the treatment of a  
disease or disorders which is dependent on the expression  
of a T3 regulated gene.

19. The use of a compound according to Claim 17 in  
which the disease or disorder is selected from  
10 hypothyroidism, hypercholesterolemia, obesity, skin  
disorders, glaucoma, cardiovascular disease, congestive  
heart failure and other endocrine disorders related to  
thyroid hormone.

20. A pharmaceutical composition comprising an  
15 effective amount of a compound according to Claim 1 or a  
pharmaceutically effective salt therefore, together with a  
pharmaceutically acceptable carrier.

21. A method of treatment of a patient with a T3  
regulated gene disorder or disease, which comprises  
20 administering to a patient in need of treatment a  
therapeutically effective amount of a compound according to  
Claim 1.

22. The method according to Claim 21 in which the  
disorder or obesity is selected from hypothyroidism,  
25 hypercholesterolemia, obesity, skin disorders, glaucoma,  
cardiovascular disease, congestive heart failure, and other  
endocrine disorders related to thyroid hormone.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/04039

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C59/68 A61K31/19 C07C65/24 C07C43/295 C07C255/37  
A61K31/085 A61K31/275 A61K31/66

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	N. YOKOYAMA: "Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine" JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 4, 17 February 1995, pages 695-707, XP002080908 WASHINGTON US see Table 3, compounds 33a and 33b; Scheme 4  ----- -/--	1-4, 8-11, 13-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 October 1998

Date of mailing of the international search report

05/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Wright, M

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/04039

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
X	<p>B. BLANK: "Thyromimetics. II. The synthesis and hypocholesteremic activity of some beta-diethylaminoethyl esters of iodinated tyroalkanoic acids" JOURNAL OF MEDICINAL CHEMISTRY, vol. 6, no. 5, September 1963, pages 560-563, XP002080909 WASHINGTON US see Tables I and III, compound XIII; page 561, compound XVIII</p> <p style="text-align: center;">---</p>	<p>1-3, 9, 10, 13-15, 17-22</p>
X	<p>DE 10 78 582 B (FARBWERKE HOECHST) 31 March 1960</p> <p style="text-align: center;">---</p> <p>see column 3, line 65 - line 70; example 3</p>	<p>1-3, 10, 13, 14, 18-22</p>
X	<p>DE 10 72 998 B (FARBWERKE HOECHST) 14 January 1960 see column 9, line 6 - line 15</p> <p style="text-align: center;">---</p>	<p>1-3, 10</p>
X	<p>P. H. MAZZOCCHI: "Synthesis of diphenyl ether models of thyroid hormones. Diphenyl ethers linked to the 3-oxo-2-azabicyclo[2.2.1]heptane ring system as substrates for conformational analysis" JOURNAL OF ORGANIC CHEMISTRY, vol. 46, no. 22, 23 October 1981, pages 4530-4536, XP002080918 EASTON US see table III</p> <p style="text-align: center;">---</p>	<p>1-3</p>
X	<p>C. M. BUSS: "The synthesis of thyromimetic substances and potential inhibitors of thyroxine" JOURNAL OF MEDICINAL CHEMISTRY, vol. 8, no. 4, July 1965, pages 469-474, XP002080919 WASHINGTON US see page 469, compound Ic</p> <p style="text-align: center;">-----</p>	<p>1-3, 10</p>

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/04039

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13, 14, 21 and 22  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 13, 14, 21 and 22  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 98/04039

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 1078582	B	NONE	
DE 1072998	B	NONE	